Steven G. Waguespack

Steven G. Waguespack

Auto-generated profile, based on publicly available information

Steven G. Waguespack

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Thyroid®
Verified
Journal Article
Open access
SWSamuel A. Wells
Samuel A. Wells
Sylvia L. AsaSylvia L. Asa
Sylvia L. Asa
HDHenning Dralle
Henning Dralle
RERosella Elisei
Rosella Elisei
DEDouglas B. Evans
Douglas B. Evans
SWSteven G. Waguespack
Steven G. Waguespack
Introduction: The American Thyroid Association appointed a Task Force of experts to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the American Thyroid Association. Methods: The Task Force identified relevant articles using a systematic PubMed search, supplemented with additional published materials, and then created evidence-based recommendations, which were set in categories using criteria adapted from the United States Preventive Services Task Force Agency for Healthcare Research and Quality. The original guidelines provided abundant source material and an excellent organizational structure that served as the basis for the current revised document. Results: The revised guidelines are focused primarily on the diagnosis and treatment of patients with sporadic medullary thyroid carcinoma (MTC) and hereditary MTC. Conclusions: The Task Force developed 67 evidence-based recommendations to assist clinicians in the care of patients with MTC. The Task Force considers the recommendations to represent current, rational, and optimal medical practice.

1 July 2015 in Thyroid®
Verified
Journal Article
Open access
GFGary L. Francis
Gary L. Francis
SWSteven G. Waguespack
Steven G. Waguespack
ABAndrew J. Bauer
Andrew J. Bauer
PAPeter Angelos
Peter Angelos
SBSalvatore Benvenga
Salvatore Benvenga
SYShunichi Yamashita
Shunichi Yamashita
Background: Previous guidelines for the management of thyroid nodules and cancers were geared toward adults. Compared with thyroid neoplasms in adults, however, those in the pediatric population exhibit differences in pathophysiology, clinical presentation, and long-term outcomes. Furthermore, therapy that may be recommended for an adult may not be appropriate for a child who is at low risk for death but at higher risk for long-term harm from overly aggressive treatment. For these reasons, unique guidelines for children and adolescents with thyroid tumors are needed. Methods: A task force commissioned by the American Thyroid Association (ATA) developed a series of clinically relevant questions pertaining to the management of children with thyroid nodules and differentiated thyroid cancer (DTC). Using an extensive literature search, primarily focused on studies that included subjects ≤18 years of age, the task force identified and reviewed relevant articles through April 2014. Recommendations were made based upon scientific evidence and expert opinion and were graded using a modified schema from the United States Preventive Services Task Force. Results: These inaugural guidelines provide recommendations for the evaluation and management of thyroid nodules in children and adolescents, including the role and interpretation of ultrasound, fine-needle aspiration cytology, and the management of benign nodules. Recommendations for the evaluation, treatment, and follow-up of children and adolescents with DTC are outlined and include preoperative staging, surgical management, postoperative staging, the role of radioactive iodine therapy, and goals for thyrotropin suppression. Management algorithms are proposed and separate recommendations for papillary and follicular thyroid cancers are provided. Conclusions: In response to our charge as an independent task force appointed by the ATA, we developed recommendations based on scientific evidence and expert opinion for the management of thyroid nodules and DTC in children and adolescents. In our opinion, these represent the current optimal care for children and adolescents with these conditions.

1 March 2011 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MAMontserrat Ayala-Ramirez
Montserrat Ayala-Ramirez
LFLei Feng
Lei Feng
MJMarcella M. Johnson
Marcella M. Johnson
SEShamim Ejaz
Shamim Ejaz
MHMouhammed Amir Habra
Mouhammed Amir Habra
CJCamilo Jimenez
Camilo Jimenez
Context: Pheochromocytomas and sympathetic paragangliomas are rare neuroendocrine tumors for which no precise histological or molecular markers have been identified to differentiate benign from malignant tumors. Objective: The aim was to determine whether primary tumor location and size are associated with malignancy and decreased survival. Design and Setting: We performed a retrospective chart review of patients with either pheochromocytoma or sympathetic paraganglioma. Patients: The study group comprised 371 patients. Main Outcome Measures: Overall survival and disease-specific survival were analyzed according to tumor size and location. Results: Sixty percent of patients with sympathetic paragangliomas and 25% of patients with pheochromocytomas had metastatic disease. Metastasis was more commonly associated with primary tumors located in the mediastinum (69%) and the infradiaphragmatic paraaortic area, including the organ of Zuckerkandl (66%). The primary tumor was larger in patients with metastases than in patients without metastatic disease (P < 0.0001). Patients with sympathetic paragangliomas had a shorter overall survival than patients with pheochromocytomas (P < 0.0001); increased tumor size was associated with shorter overall survival (P < 0.001). Patients with sympathetic paragangliomas were twice as likely to die of disease than patients with pheochromocytomas (hazard ratio = 1.93; 95% confidence interval = 1.20–3.12; P = 0.007). As per multivariate analysis, the location of the primary tumor was a stronger predictor of metastases than was the size of the primary tumor. Conclusions: The size and location of the primary tumor were significant clinical risk factors for metastasis and decreased overall survival duration. These findings delineate the follow-up and treatment for these tumors.

1 December 2013 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
MAMontserrat Ayala-Ramirez
Montserrat Ayala-Ramirez
SJSina Jasim
Sina Jasim
LFLei Feng
Lei Feng
SEShamim Ejaz
Shamim Ejaz
FDFerhat Deniz
Ferhat Deniz
MHMouhammed Amir Habra
Mouhammed Amir Habra
Objective: Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. Herein, we describe the clinical features and outcomes for a large series of ACC patients.Design and methods: Retrospective review of ACC patients seen at The University of Texas MD Anderson Cancer Center from 1998 through 2011.Results: A total of 330 patients with median age at diagnosis of 48.5 years; 12 (3.6%) patients were under 18 years. Hormonally functioning tumors represented 41.8% (n=138) of all cases. Surgical resection for the primary tumor was done in 275 (83.3%) patients (45 at MD Anderson (16.4%)). For those who had surgical resection, the median local-recurrence-free time was 1.04 years. Factors associated with local recurrence included positive surgical margins (P=0.007) and advanced disease stage (P=0.026). Median overall survival time for all patients was 3.21 years. Median survival times were 24.1, 6.08, 3.47, and 0.89 years for stages I, II, III, and IV respectively. In multivariable analysis, older age, functioning tumors, and higher disease stage remained significant prognostic factors associated with poor survival.Conclusion: ACC prognosis remains poor with the use of currently available treatments. Older age, functioning tumors, and incomplete resections are clinical factors associated with poor survival. Surgical expertise is important to achieve complete resections and to improve outcome.

9 July 2004 in Head & Neck
Verified
Journal Article
Closed access
PDF file
NBNaifa L. Busaidy
Naifa L. Busaidy
CJCamilo Jimenez
Camilo Jimenez
MHMouhammed Amir Habra
Mouhammed Amir Habra
PSPamela N. Schultz
Pamela N. Schultz
AEAdel K. El‐Naggar
Adel K. El‐Naggar
RVRena Vassilopoulou‐Sellin
Rena Vassilopoulou‐Sellin

1 November 2010 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
RTR. Michael Tuttle
R. Michael Tuttle
DBDouglas W. Ball
Douglas W. Ball
DBDavid Byrd
David Byrd
RDRaza A. Dilawari
Raza A. Dilawari
GDGerard M. Doherty
Gerard M. Doherty
LWLori J. Wirth
Lori J. Wirth